search
Back to results

The Effect of Probiotic and Zinc Supplementation on the Common Cold

Primary Purpose

Common Cold

Status
Enrolling by invitation
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Probiotic
Placebo
Sponsored by
Lund University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Common Cold

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy adults

Exclusion Criteria:

  • Diagnosed gastrointestinal disorders
  • Autoimmune diseases or immuno compromized
  • Antibiotic treatment in the last month

Sites / Locations

  • Lunds universitet

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

Placebo

Probiotic

Arm Description

Rice flour

Probiotic bacteria, yeast, zinc and rice brand

Outcomes

Primary Outcome Measures

Symptoms severity
Decrease in the severity of symptoms will be determined using a common cold questionnaire.

Secondary Outcome Measures

Composition of gut and oral microbiome
Change in gut and oral microbiome will be measured using 16SrRNA and 18SrRNA sequencing
IgA
Changes in levels of IgA in saliva and/or feces will be measured using ELISA
Duration of symptoms
Decrease in duration of cold will be determined using a common cold questionnaire
Number of colds
Decrease in number of colds will be determined using a common cold questionnaire

Full Information

First Posted
December 3, 2020
Last Updated
April 11, 2022
Sponsor
Lund University
Collaborators
Coradil AB
search

1. Study Identification

Unique Protocol Identification Number
NCT04672850
Brief Title
The Effect of Probiotic and Zinc Supplementation on the Common Cold
Official Title
The Effect of Probiotic and Zinc Supplementation on the Common Cold in Healthy Adults
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Enrolling by invitation
Study Start Date
January 27, 2021 (Actual)
Primary Completion Date
November 2022 (Anticipated)
Study Completion Date
November 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Lund University
Collaborators
Coradil AB

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The purpose with this study is to investigate the preventative effect of a supplement containing a combination of probiotic bacteria and fungi as well as zinc on the common cold. The hypothesis is that it will shorten the duration, alleviate the severity of symptoms or even decrease the number of infectons during the intervention period. This study is a randomzed placebo controlled human study were healthy adults will consume the supplement for three months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Common Cold

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
Double-blinded
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Rice flour
Arm Title
Probiotic
Arm Type
Active Comparator
Arm Description
Probiotic bacteria, yeast, zinc and rice brand
Intervention Type
Dietary Supplement
Intervention Name(s)
Probiotic
Intervention Description
The participants will consume 2 capsules daily for three months
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
The participants will consume 2 capsules daily for three months
Primary Outcome Measure Information:
Title
Symptoms severity
Description
Decrease in the severity of symptoms will be determined using a common cold questionnaire.
Time Frame
Three months
Secondary Outcome Measure Information:
Title
Composition of gut and oral microbiome
Description
Change in gut and oral microbiome will be measured using 16SrRNA and 18SrRNA sequencing
Time Frame
Three months
Title
IgA
Description
Changes in levels of IgA in saliva and/or feces will be measured using ELISA
Time Frame
Three months
Title
Duration of symptoms
Description
Decrease in duration of cold will be determined using a common cold questionnaire
Time Frame
Three months
Title
Number of colds
Description
Decrease in number of colds will be determined using a common cold questionnaire
Time Frame
Three months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy adults Exclusion Criteria: Diagnosed gastrointestinal disorders Autoimmune diseases or immuno compromized Antibiotic treatment in the last month
Facility Information:
Facility Name
Lunds universitet
City
Lund
Country
Sweden

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Only group data will be shared

Learn more about this trial

The Effect of Probiotic and Zinc Supplementation on the Common Cold

We'll reach out to this number within 24 hrs